Abstract-The molecular mechanisms of the contribution of angiotensin II type-1 receptor blockers to neuronal protection are still unclear. Here, we investigated the effect of angiotensin II type-2 (AT 2 ) receptor stimulation on neurons and cognitive function involving a new neuroprotective factor, methyl methanesulfonate sensitive 2 (MMS2 
S
troke is one of the leading causes of disability and death in the industrialized world; however, radical treatment for stroke is limited. Therefore, therapy to prevent stroke is based on treating an individual's underlying risk factors for stroke, such as hypertension, atrial fibrillation, and diabetes. Recent major clinical research such as the Perindopril Protection Against Recurrent Stroke Study (PROGRESS), 1 Study on Cognition and Prognosis in the Elderly (SCOPE), 2 Losartan Intervention For Endpoint reduction in hypertension study (LIFE), 3 and Acute Candesartan Cilextil Evaluation in Stroke Survivors (ACCESS) 4 studies indicates that blockade of the renin-angiotensin system (RAS) is effective to prevent a first or recurrent stroke, atrial fibrillation, and type 2 diabetes mellitus beyond blood pressure lowering. However, the detailed molecular mechanisms of preventing the onset of such pathologic conditions are still an enigma.
Angiotensin II (Ang II) is the principal vasoactive substance of the RAS, having a variety of physiological actions, including vasoconstriction, aldosterone release, and cell growth. 5 Ang II binds 2 major receptors, the Ang II type-1 (AT 1 ) receptor and type-2 (AT 2 ) receptor. AT 1 receptor blockers (ARBs) have been widely used as antihypertensive drugs, with the expectation of vascular protective effects. Although the majority of Ang II actions are mediated via the AT 1 receptor, evidence has accumulated that the AT 2 receptor not only opposes the AT 1 receptor but also has unique effects beyond an interaction with AT 1 receptor signaling. Recently, we reported the effects of the AT 2 receptor on ischemic brain regions using a middle cerebral artery (MCA) occlusion model in AT 2 receptor-deficient (Agtr2Ϫ) mice. 6 Agtr2Ϫ mice displayed a larger ischemic area compared with wild-type mice, and pretreatment with a nonhypotensive dose of an ARB, valsartan, significantly reduced the ischemic area in wild-type mice but not in Agtr2Ϫ mice through a reduction of oxidative stress in the ischemic brain and an increase in cerebral blood flow in the penumbral region, independent of blood pressure lowering, suggesting that activation of the AT 2 receptor or blockade of the AT 1 receptor attenuates brain injury.
Stroke is also one of the most important causes of cognitive impairment and dementia in the aging population. Poor cognitive performance significantly impairs social interaction and the quality of life of patients. However, once there is cognitive decline, little can be done therapeutically to reverse the symptoms. Although the management of blood pressure is effective to prevent cognitive decline, a major clinical study (SCOPE 2 ) and a clinical double-blind study 7 have proved that ARBs have a further therapeutic effect on impaired cognitive function beyond their antihypertensive effects compared with other antihypertensive drugs.
AT 2 receptors are also reported to be expressed in areas related to learning and control of motor activity 8, 9 and in fetal tissues but are present at low levels in adult tissues and are re-expressed in certain pathological conditions, such as neuronal injury 10 -12 and vascular injury, 13 suggesting that activation of the AT 2 receptor may play a pivotal role in the repair and regeneration of injured tissues. Recent studies have demonstrated the possibility that stimulation of AT 2 receptors may promote cell differentiation and regeneration in neuronal tissue. 5, 14 Li et al 15 reported that AT 2 receptor stimulation supported neuronal survival and neurite outgrowth in response to ischemia-induced neuronal injury. Moreover, Gendron et al 16 demonstrated that Ang II induces neural differentiation and neurite outgrowth via mitogen-activated protein kinase or NO 17 through AT 2 receptor activation and is involved in cerebellum development. 18 Therefore, after focal brain injury, AT 2 receptor stimulation could prevent damage of neurons or activate neural repair systems. However, the earliest events associated with activation of AT 2 receptor and the contribution of AT 2 receptor signaling to cognitive decline remains unclear.
Methyl methanesulfonate sensitive 2 (MMS2) belongs to a family of ubiquitin-conjugating enzyme variants that are highly similar to ubiquitin-conjugating enzymes E2 (Ubc) and forms a complex with Ubc-13. 19, 20 The MMS2/Ubc-13 complex has been reported to play an important role in DNA repair through a ubiquitin-proteasome system (UPS). 21 DNA damage occurs with central nervous system (CNS) injury, and defects in repair mechanisms are associated with neurodegenerative diseases. 22 Abnormalities of the UPS in the brain contribute to Parkinson disease, Alzheimer disease, prion disease, amyotrophic lateral sclerosis, and polyglutamine disease. 23 Recently, MMS2 was reported to be highly expressed in the rat brain in late embryonic development and then to fall markedly during maturation of the CNS, 24 suggesting that MMS2 plays a pivotal role in neuronal development and differentiation. However, the association of MMS2 with CNS injury has never been studied.
Here, we found that Ang II induced MMS2 mRNA expression in neurons through AT 2 receptor stimulation. Focusing on the AT 2 receptor-MMS2 signaling cascade, we demonstrated potential roles of AT 2 receptor stimulation in neural protection and preservation of cognitive function after focal ischemia.
Materials and Methods
An expanded Materials and Methods section is available online at http://hyper.ahajournals.org.
Cell Culture
To assess the effects of Ang II on neural differentiation, we used in vitro fetal mouse neurospheres prepared as described previously. 25 AT 2 receptor-deficient mouse (Agtr2Ϫ; based on C57BL/6J strain bred in our laboratory) and wild-type mouse (Agtr2ϩ) fetal brain tissue was dissected into cells. Counting neurospheres was performed in the view at ϫ20 magnification with an Axioskop microscope (Carl Zeiss).
Immunoblot Analysis
Total protein was prepared from neurospheres, and immunoblotting was performed as described previously 26 using anti-MAP2 (Chemicon International Inc, Temecula, Calif), anti-␤III tubulin, anti-glial fibrillary acidic protein (Promega Corporation, Madison, Wis), and anti-MMS2 (Santa Cruz Inc, Santa Cruz, Calif) antibodies. Densitometric analysis was performed using an image scanner (EPSON GT-8000, Ricoh System Kaihatsu Company Ltd) and National Institutes of Health imaging software.
Immunofluorescence
Neurospheres were fixed with an ethanol and methanol solution (1:1 mixed) before incubation with rabbit polyclonal anti-mouse AT 1 , AT 2 receptor antibody (Santa Cruz Inc), and mouse monoclonal anti-MMS2 antibody (Zymed Laboratories Inc, South San Francisco, Calif). The secondary antibody was goat anti-rabbit or anti-mouse Cy3-conjugated antibody (Jackson ImmunoResearch, West Grove, Pa). Cells were counterstained with 4Ј,6-diamidino-2-phenylindole. Images were viewed at ϫ40 magnification with an Axioskop microscope (Carl Zeiss) using image analysis software (AxioVison, Carl Zeiss).
MMS2 Small Interfering RNA Assay
For small interfering RNA (siRNA) assay, neural stem cells isolated from the mouse fetal cortex and neurospheres were transiently transfected with negative control siRNA or MMS2-specific siRNA, a mixture of 3 siRNAs designed by B-Bridge using Lipofectamine PLUS (Invitrogen). Thirty-six hours after transfection, cells were observed and treated. Knockdown of MMS2 gene was evaluated by immunoblot using anti-MMS2 antibody (Zymed Laboratories Inc). The mixtures of siRNAs targeting to MMS2 are shown in Supplemental Table II (available online at http://hyper.ahajournals.org).
Immunohistochemical Study
Frozen, enzymatically intact, 10-m-thick sections were prepared from mouse brain 24 hours after MCA occlusion and fixed with 10% formaldehyde solution before incubation with mouse polyclonal anti-MMS2 antibody (Zymed Laboratories Inc). After incubation, sections were stained by diaminobenzidine staining using an ABC staining kit (DakoCytomation).
Animals and Treatment
This study was performed in accordance with the National Institutes of Health guidelines for the use of experimental animals. All of the animal studies were reviewed and approved by the Animal Studies Committee of Ehime University. An ARB, valsartan (provided by Novartis Pharma AG), was administered at a dose of 3 mg/kg per day IP via an osmotic minipump (Alzet model 1002, Durect Corporation) implanted IP 10 days before MCA occlusion. Blood pressure was measured by the tail-cuff method (MK-1030, Muromachi Co, Ltd).
MCA Occlusion
Focal cerebral ischemia was induced by occlusion of the MCA in 10-week-old mice by means of an intraluminal filament technique according to a method described previously. 27, 28 Brain samples were obtained 24 hours after MCA occlusion, and mRNA was isolated using Sepasol-RNAI (Nacalai Tesuque Inc). Neurological deficit was evaluated 24 hours after MCA occlusion using the neurological scores developed by Hara et al. 29 
Procedure of Passive Avoidance Test
A shuttle avoidance cage (32ϫ12.5ϫ15 cm; Melquest) and an isolation cabinet (48ϫ42ϫ37 cm; Melquest) were used. Mice were individually placed in a chamber and given 20 inescapable electric shocks (0.3 mA) of 10 seconds duration at intervals of 2 seconds. The number of escape failures was recorded. Escape failure was defined as a noncrossing response during shock delivery.
Real-Time RT-PCR Method
Real-time quantitative RT-PCR was performed with a SYBR green I kit (MJ Research, Inc). PCR primers for the AT 1 , AT 2 , and angiotensin II type-4 receptors (insulin regulated aminopeptidase [IRAP] ) and MMS2 are shown in Supplemental Table I .
In Vivo MMS2-siRNA Transfer
We performed in vivo MMS2-siRNA transfer according to the method described previously. 30 Mice were implanted with a stainless steel cannula in a unilateral cerebral ventricle. The stereotaxic coordinates were 0.5 mm posterior and 1.0 mm lateral to the bregma. ICV administration of 1 L of naked siRNA (50 g) was performed with the cannula. Animals were allowed 2 days of recovery before MCA occlusion. Transfection efficiency was evaluated by observation of stained cells using Cy3-labeled siRNA injection.
Statistical Analysis
Values are expressed as meanϮSE in the text and figure. Data were analyzed by 2-way ANOVA. If a statistically significant effect was found, post hoc analysis was performed to detect the difference between the groups. A value of PϽ0.05 was considered to be statistically significant.
Results

Effects of AT 2 Receptor Stimulation on Neural Differentiation
To assess the effect of Ang II stimulation on neural differentiation, we prepared neurospheres from mouse fetal brain cortex. As reported previously, 31 immunofluorescent staining clearly showed that both AT 1 and AT 2 receptors were expressed in mouse neurospheres ( Figure 1A) . Usually, neurospheres keep floating in basic fibroblast growth factorcontaining neural stem cell-specific medium, but after attaching to culture dishes, differentiate into neurons, astrocytes, or oligodendrocytes. Administration of Ang II (10 Ϫ7 mol/L) for 3 days significantly increased not only a total number of neurospheres but also attachment of neurospheres ( Figure 1B) , even in basic fibroblast growth factor-containing neural stem cell-specific medium, and induced their differentiation into neuron-like cells. Similarly, as shown in Figure 1C , Ang II stimulation increased the number of cells expressing mature neural cell markers, such as ␤III-tubulin and MAP2 by immunoblot analysis. Interestingly, no significant change was found in the expression of a mature glial cell marker, glial fibrillary acidic protein ( Figure 1D ). These effects of Ang II were further enhanced by treatment with an ARB, valsartan (10 Ϫ5 mol/L), and were markedly inhibited by an AT 2 receptor-specific blocker, PD123319 (10 Ϫ5 mol/L; Figure 1B  through 1D) . Moreover, administration of Ang II and valsartan to neurospheres generated from Agtr2Ϫ mice failed to increase the number of attached spheres ( Figure 1E ), indicating that Ang II-induced neural differentiation is mediated via AT 2 receptor stimulation.
Association of AT 2 Receptor Stimulation and MMS2 Induction in Neural Differentiation
To further examine the mechanism of neural differentiation induced by AT 2 receptor stimulation, we focused on MMS2 expression in neurons. In cultured rat neuronal cells, we observed that an increase in mRNA expression of MMS2 reached a peak just before or after birth, and a similar expression pattern was observed for the AT 2 receptor. 32 Real-time RT-PCR analysis showed that Ang II increased MMS2 mRNA expression in mouse neurospheres, and this increase was enhanced by valsartan but inhibited by PD123319 (Figure 2A) . Similar results were obtained in the protein expression of MMS2 by immunoblot ( Figure 2B ), indicating that Ang II-induced MMS2 expression was via AT 2 receptor activation.
MMS2 is reported to be expressed in rat fetal brain and to affect brain development 24 ; however, the expression and effect of MMS2 on neurospheres have never been studied. Immunofluorescent staining clearly showed that MMS2 was expressed in mouse neurospheres ( Figure 3A) . Therefore, we assessed the function of MMS2 in neurospheres using siRNA for gene knockdown of MMS2. Treatment of neurospheres with MMS2-siRNA caused failure to "maintain" tight sphere formation as shown in Figure 3B and caused their collapse and a reduction in sphere number ( Figure 3C ). Next, we performed MMS2-siRNA treatment in neural stem cells that were just isolated from mouse fetal cortex. Treatment of neural stem cells with MMS2-siRNA caused failure to "generate" neurospheres, resulting in a reduction of sphere number ( Figure 3D ). The Ang II-induced increase in attached sphere number induced by valsartan was significantly inhibited in neurospheres treated with MMS2-siRNA, as shown in Figure 3E . MMS2-siRNA treatment in neurospheres had no effect on mRNA expressions of AT 1 and AT 2 receptors ( Figure 3F ). These results indicate that Ang II-induced neural differentiation was via stimulation of the AT 2 receptor and involved the induction of MMS2 expression.
mRNA Expression of Angiotensin Receptors After Focal Ischemia
Next, to assess AT 2 receptor-induced neural differentiation in vivo, mice were subjected to MCA occlusion to the effect of the AT 2 receptor after brain injury. The left MCA was permanently occluded by insertion of a nylon monofilament coated with silicon resin. Evaluation of the expression of angiotensin receptors in the ischemic and nonischemic areas of the brain after MCA occlusion showed that the AT 2 receptor mRNA level was significantly increased in the ischemic area compared with the nonischemic area 24 hours after MCA occlusion, whereas AT 1 receptor mRNA expression was not significantly changed (Figure 4) . Angiotensin IV, which is also a ligand for IRAP, is reported to be involved in long-term potentiation of neurons and associative and spatial learning. 33 However, IRAP mRNA expression was significantly decreased not only in the ischemic area but also in the nonischemic area after MCA occlusion ( Figure 4 ). These findings suggest that the AT 2 receptor may play a more important role in neural protection or cognitive function after brain injury than angiotensin IV-IRAP signaling. Therefore, we focused on the functions of the AT 2 receptor after ischemic stoke in the following experiments, using Agtr2Ϫ mice.
Effects of AT 2 Receptor Signaling on Cognitive Function After Focal Ischemia
In previous studies, we demonstrated the possible inhibition of stroke size via AT 2 receptor stimulation. 6 Here, we examined cognitive function after stroke to evaluate neuronal loss in the injured brain. To assess the effects of MCA occlusion on subsequent learning and memory, Agtr2ϩ and Agtr2Ϫ mice were subjected to 20 trials of a shuttle avoidance test just before and 3 days after MCA occlusion. Because Agtr2Ϫ mice display a lower neurological score compared with Agtr2ϩ mice, as described previously, 6 mice with similar neurological scores were chosen to exclude any difference in locomotor activity in these experiments. Focal brain injury by MCA occlusion in Agtr2ϩ mice resulted in a lower avoidance rate and a lower total response rate, which were evaluated by the avoidance rate and escape rate. Interestingly, we demonstrated that the avoidance rate in Agtr2Ϫ mice was significantly lower before MCA occlusion and was more markedly impaired than in age-matched Agtr2ϩ litter mates ( Figure 5A ). Moreover, IP administration of a nonhypotensive dose of valsartan via an osmotic minipump at a dose of 3 mg/kg per day for 10 days before MCA occlusion significantly improved the avoidance rate and also improved the total response rate ( Figure 5B) . Interestingly, treatment with valsartan enhanced cognitive function before MCA occlusion, indicating that the AT 2 receptor plays a pivotal role in cognition even before focal cerebral ischemia.
Effect of MMS2 on Cognitive Function After Focal Ischemia
Finally, we analyzed the effect of MMS2 on cognitive function after focal ischemia. Brain samples were obtained 24 hours after MCA occlusion. MMS2 mRNA expression was increased in the ischemic brain region in Agtr2ϩ mice but not in Agtr2Ϫ mice ( Figure 6A ). Valsartan significantly increased MMS2 mRNA expression in the ischemic area in Agtr2ϩ mice. Immunohistochemical staining of MMS2 also showed an increase of MMS2 expression in the ischemic brain of Agtr2ϩ mice ( Figure 6B ). These findings suggest that AT 2 receptor signaling could contribute to neural repair via MMS2 expression after brain injury. To further investigate the effect of MMS2 on cognitive function after focal ischemia, we performed the ICV administration of MMS2-siRNA. Treatment with MMS2-siRNA showed more impaired avoidance rate after MCA occlusion compared with that in negative control siRNA-transfected mice ( Figure 6C ), suggesting that inhibiting the increase in MMS2 expression by knocking down of the MMS2 gene in vivo enhanced the decline in cognitive function after stroke.
Discussion
In this study, we demonstrated that the direct effects of AT 2 receptor stimulation contribute to neural differentiation and could prevent the cognitive decline after brain injury. First, in cultured neurons, AT 2 receptor stimulation enhanced the differentiation of neurospheres and induced MMS2 expression, which affects neural differentiation or protection, demonstrated by a gene knockdown assay of MMS2. Second, we showed that Agtr2Ϫ mice exhibited greater impairment of cognitive function after focal cerebral ischemia. Third, MMS2 induction after focal ischemia was found in wild-type mice but not in Agtr2Ϫ mice. Therefore, these experimental results and our previous report 6 This study demonstrated the association of AT 2 receptor stimulation with MMS2 induction. Although the signaling cascade from AT 2 receptor stimulation to MMS2 induction remains unclear, downstream targets of the AT 2 receptor may be involved in such a cascade. The AT 2 receptor belongs to the superfamily of G protein-coupled receptors and negatively regulates cell proliferation via signaling pathways that mainly involve activation of tyrosine phosphatases, such as Src homology 2 domain-containing protein-tyrosine phosphatase 1 (SHP-1), and inhibition of protein kinases. 34 SHP-1 is reported to be a critical regulator of developmental signals leading to terminal differentiation and myelin sheath formation by oligodendrocytes, 35 suggesting that SHP-1 may be involved in AT 2 receptor-induced neural differentiation. Moreover, we have recently cloned AT 2 receptor-interacting protein, which interacts with the C-terminal tail of the AT 2 receptor, and it has been indicated recently to cooperate with the AT 2 receptor to trans-inactivate receptor tyrosine kinases. 36 Our recent experimental results indicate that interaction of SHP-1 and AT 2 receptor-interacting protein may be involved in MMS2 upregulation by AT 2 receptor stimulation. 32 Further study will be needed to confirm the steps of the signaling cascade from AT 2 receptor stimulation to MMS2 transactivation.
Here, we showed that lack of the MMS2 gene caused failure to maintain sphere formation of neurospheres and generation of neurospheres from neural stem cells. It can be speculated that MMS2 seems to act as a control factor of neural cell differentiation, survival, and fate. The MMS2/ Ubc-13 complex has been reported to play an important role in DNA repair through a UPS, 21 and MMS2 is also necessary for error-free lesion bypass in the RAD6 pathway with cell cycle regulation. 37 After cerebral ischemia, oxidative DNA damage occurs in a more extensive area than that where cell death is recognized. 38 Because severe DNA damage triggers neuronal cell apoptosis, such extended DNA damage could result in more prolonged cell dysfunction and eventual neuronal loss. 38, 39 To prevent neuronal loss, a complex DNA repair system network is activated after cerebral ischemia. 22 Therefore, MMS2 may play an important role in neural protection after stroke through the DNA repair system.
The detail mechanism of the decrease in mRNA expression of IRAP after MCA occlusion is unclear. However, focal cerebral ischemia induced an imbalance of blood flow in both hemispheres through secondary remote effects 40 or diaschisis. 41 To prevent neural loss and avoid the development of a necrosis, neurons induce preconditioning and decrease genes involved in metabolic pathways. 42 IRAP regulates glucose metabolism through glucose uptake by regulating trafficking of GLUT4. Therefore, focal ischemia may reduce IRAP expression to reduce glucose metabolism for the inhibition of neuronal loss.
Ang II inhibited the induction of long-term potentiation in rat hippocampal granule cells, an ARB blocked the inhibition of long-term potentiation, 43 and an angiotensin-converting enzyme inhibitor attenuated the age-related impairment of learning and memory, 44 suggesting that blockade of the RAS also inhibits the cognitive decline not only through its hypotensive effect but also by other mechanisms. Agtr2Ϫ mice have been reported to exhibit attenuation of exploratory behavior and anxiety-like behavior 45 and abnormality in water intake. 30 In our experiments on behavioral tasks, Agtr2Ϫ mice showed a less social approach to a strange mouse and exhibited anxiety behavior (Supplemental Figure I , available at http://hyper.ahajournals.org), indicating that Agtr2Ϫ mice may have a neuropsychiatric disorder by nature. Agtr2Ϫ mice are reported to have an increased number of cells in the brain 46 because of abnormal regulation of apoptosis. Indeed, we also observed an increased cell number around the hypothalamus of Agtr2Ϫ mice (32Ϯ3.1 in wild-type mice, 56.3Ϯ2.4 in Agtr2Ϫ mice at ϫ20 magnification detected by hematoxylin/eosin staining). These results suggest that lack of the AT 2 receptor gene may generate an abnormality of brain development. Indeed, in humans, mutations of the AT 2 receptor located on the X chromosome were found in a female patient with mental retardation, 47 indicating that the AT 2 receptor gene may be involved in brain development and neural maturation.
Perspectives
Our present findings demonstrate the possibility that the AT 2 receptor is an important molecular determinant of neural differentiation, and AT 2 receptor activation prevents the cognitive decline after focal brain injury, involving a new neuroprotective factor, MMS2. Therefore, we expect that relative stimulation of AT 2 receptor signaling by ARB treatment could have a therapeutic advantage to prevent neurological disorders after stroke. 
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